Irrfan Khan’s battle with neuroendocrine tumor: Early signs, risk factors, and diagnosis challenges

Acclaimed Indian actor Irrfan Khan passed away at 53 after a battle with a rare neuroendocrine tumor (NET). Diagnosed in 2018 ...

Steve Jobs died from ‘rare’ pancreatic cancer: What was his diagnosis, and what are the early signs of it

Steve Jobs succumbed to a rare pancreatic neuroendocrine tumor. This cancer type differs significantly from common pancreatic ...
Pancreatic Cancer Action Network

Pancreatic Neuroendocrine Tumors: PanCAN Offers Support, Resources, Ways to Connect

PanCAN Chief Scientific and Medical Officer Anna Berkenblit discusses how PanCAN supports all patients diagnosed with ...
Cure Today

Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...
News Medical

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut ...
ascopubs.org

Efficacy of peptide receptor radionuclide therapy in combination with capecitabine and temozolomide in neuroendocrine tumors: A systematic review and meta-analysis.

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial of 225Ac-SSO110 in Patients with Extensive-Stage Small Cell Lung Cancer or Merkel Cell Carcinoma

Ac-SSO110 has received U.S. FDA Orphan Drug Designation Initial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026 Potential to address a broad range of neuroendocrine cancers BERLIN, ...
ascopubs.org

Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET): Single institution experience over 15 years.

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial. This is an ASCO Meeting ...